SUBSCRIBE
SUBSCRIBE

Biogen

NEWS
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
FDA
FDA Approves Biogen Idec, Inc. (Massachusetts)'s Multiple Sclerosis Drug Plegridy
August 18, 2014
 · 
8 min read
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Job Trends
Why People Love Working For Big Pharmas Like Biogen Idec, Inc. (Massachusetts), Celgene, And Gilead Sciences, Inc.
April 18, 2014
 · 
1 min read
Genetown
Why Biogen Idec, Inc. (Massachusetts) Got Out of the Corporate VC Business
January 27, 2012
 · 
1 min read
Genetown
Biogen Idec, Inc. (Massachusetts), Bayer AG MS Drugs Aren’t Cost Effective, Journal of Neurology Reveals
July 21, 2011
 · 
1 min read
Biotech Bay
Copying Biotech Medicine Attracts More Drugmakers, Including Amgen and Biogen Idec, Inc. (Massachusetts)
January 14, 2011
 · 
1 min read
Pharm Country
Roche Holding AG, Johnson & Johnson and Biogen Idec, Inc. (Massachusetts) Prodded by FDA for More Neglected Disease Medicines
June 18, 2010
 · 
1 min read
Genetown
Biogen Idec, Inc. (Massachusetts) Hopes To Have PML-Related Test By Year-End
March 26, 2009
 · 
1 min read
Drug Development
Genentech, Inc. and Biogen Idec, Inc. (Massachusetts) Rituxan May Heal Common Kidney Condition
August 7, 2008
 · 
1 min read
Policy
Carl Icahn Says Biogen Idec, Inc. (Massachusetts) Documents From Failed Sale Process Contain ‘Untruths’
June 5, 2008
 · 
1 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
May 22, 2026
 · 
15 min read
Press Releases
The ADDF Highlights Encouraging Progress Toward Targeting Multiple Alzheimer’s Pathologies in Biogen’s Phase 2 Tau Study
May 14, 2026
 · 
3 min read
Press Releases
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease
May 14, 2026
 · 
8 min read
Press Releases
Biogen Completes Acquisition of Apellis Pharmaceuticals
May 14, 2026
 · 
21 min read
Press Releases
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
May 14, 2026
 · 
11 min read
Press Releases
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease
May 8, 2026
 · 
18 min read
Press Releases
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
April 20, 2026
 · 
14 min read
Press Releases
Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer’s Disease at the 78th American Academy of Neurology’s Annual Meeting
April 9, 2026
 · 
10 min read
Press Releases
Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform
April 7, 2026
 · 
3 min read
Press Releases
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
March 31, 2026
 · 
32 min read
Load More